On May 16, 2012, the New York Times reported on a unique study being conducted to test for possible prevention for Alzheimer’s disease. The study is being conducted on 300 members of an extended family from Medellin, Colombia, who exhibit a genetic mutation that leads to a high incidence of Alzheimer’s and dementia, often with early onset. The study aims to examine whether the proposed drug, Crenezumab, can delay memory decline or brain changes and focuses on prevention by administering the drug prior to the onset of any symptoms. The study could have a wide-ranging impact on those affected by Alzheimer’s, and for members of this Colombian family deeply affected by Alzheimer’s, it offers them a glimmer of hope.